Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn’s disease
Dermatology Reports · 12.05.2026
DOI: 10.4081/dr.2026.10823 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Reports, online erschienen am 12.05.2026. Verfasst von Cosimo Di Raimondo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Dear Editor, Mogamulizumab is a humanized, defucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4), expressed on malignant T cells in cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides and Sézary syndrome. By enhancing antibody-dependent cellular cytotoxicity, mogamulizumab selectively depletes CCR4-positive malignant lymphocytes and has demonstrated significant clinical activity in advanced CTCL, including in patients refractory to multiple prior therapies. [...]
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome.
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome.
- Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome; Department of Systems Medicine, University of Rome "Tor Vergata", Rome.
Zitieren
APA
Di Raimondo, C., Mortato, E., Di Domenico, P. P., Bianchi, L., & Galluzzo, M. (2026). Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn’s disease. Dermatology Reports. https://doi.org/10.4081/dr.2026.10823
Vancouver
Di Raimondo C, Mortato E, Di Domenico PP, Bianchi L, Galluzzo M. Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn’s disease. Dermatology Reports. 2026. doi:10.4081/dr.2026.10823
BibTeX
@article{DiRaimondo2026,
author = {Di Raimondo, Cosimo and Mortato, Edoardo and Di Domenico, Pier Paolo and Bianchi, Luca and Galluzzo, Marco},
title = {Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn’s disease},
journal = {Dermatology Reports},
year = {2026},
doi = {10.4081/dr.2026.10823}
}
EUVIMED